Tag: Sanofi

Ben and EpiPens

Sanofi Presses Court Battle with Mylan in Appeal of EpiPen Antitrust...

With billions at stake, Sanofi ups the ante with Mylan in their EpiPen suit.
Dupixent

FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...

Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
Monopoly Man

Sanofi Seeking Billions from Mylan in EpiPen Antitrust Suit

Sordid details of anticompetitive behavior alleged in court filing.
dupilumab

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
AR101+dupilumab

Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...

Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
AR101+dupilumab

Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...

Study scheduled to commence next week.
dupilumab

Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...

"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
Paliforzia (AR101)

Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate

The company announces their timeline for continued progress toward an FDA approved standardized therapy.
Peanut Allergy Therapy

Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy

More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
Kaleo Booth

Auvi-Q Takes Center Stage at School Nurse Conference

One example of the changing market dynamics for epinephrine auto-injectors in light of recent developments.